Toward a neuroimaging treatment selection biomarker for major depressive disorder

JAMA Psychiatry

Volumn 70, Issue 8, 2013, Pages 821-829

  McGrath, Callie L ^a,b   Kelley, Mary E ^b   Holtzheimer, Paul E ^c   Dunlop, Boadie W ^a   Craighead, W Edward ^a   Franco, Alexandre R ^d   Craddock, R Cameron ^e,f   Mayberg, Helen S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e CHILD MIND INSTITUTE   (United States)

^f NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ESCITALOPRAM; FLUORODEOXYGLUCOSE F 18;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HAMILTON SCALE; HUMAN; INSULA; MAJOR DEPRESSION; MALE; MOOD DISORDER; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84882408136     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.143     Document Type: Article

References (72)

1. Kessler RC, Berglund P, Demler O, et al National Comorbidity Survey Replication. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105. (Pubitemid 37432885)
2. Birnbaum HG, Kessler RC, Kelley D, Ben-Hamadi R, Joish VN, Greenberg PE. Employer burden of mild, moderate, and severe major depressive disorder: Mental health services utilization and costs, and work performance. Depress Anxiety. 2010;27(1):78-89.
3. Judd LL, Akiskal HS, Zeller PJ, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry. 2000;57(4):375-380. (Pubitemid 30202328)
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision.Washington, DC: American Psychiatric Association; 2000.
5. Kennedy SH, Lam RW, Parikh SV, Patten SB, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults: Introduction. J Affect Disord. 2009;117(suppl 1):S1-S2.
6. American Psychiatric Association. Treating Major Depressive Disorder: A Quick Reference Guide. Washington, DC: American Psychiatric Association; 2010:1-28.
7. National Institute for Health and Clinical Excellence. Depression: The Treatment and Management of Depression in Adults. London, England: National Institute for Health and Clinical Excellence; 2009. NICE clinical guideline 90.
8. Gaynes BN,Warden D, Trivedi MH, Wisniewski SR, FavaM, Rush AJ. What did STAR?D teach us? results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60(11):1439-1445.
9. Holtzheimer PE,Mayberg HS. Stuck in a rut: Rethinking depression and its treatment. Trends Neurosci. 2011;34(1):1-9.
10. Kessler RC, Akiskal HS, AmesM, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry. 2006;163(9): 1561-1568. (Pubitemid 44465756)
11. Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ. Symptomatic and functional improvement in employed depressed patients: A double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol. 2011;31(5):569-576.
12. Kapur S, Phillips AG, Insel TR.Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry. 2012;17(12):1174-1179.
13. Saijo N. Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. Cancer Treat Rev. 2012;38(1):63-67.
14. Welch TD, Yang EH, Reeder GS, Gersh BJ. Modern management of acutemyocardial infarction. Curr Probl Cardiol. 2012;37(7):237-310.
15. Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression: A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl. 1993;(21):30-34. (Pubitemid 23271368)
16. Irwin MR,Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun. 2007;21(4):374-383. (Pubitemid 46528684)
17. Müller N, Myint A-M, Schwarz MJ. Inflammatory biomarkers and depression. Neurotox Res. 2011;19(2):308-318.
18. Arana GW, Baldessarini RJ, Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry: Commentary and review. Arch Gen Psychiatry. 1985;42(12):1193-1204. (Pubitemid 16191180)
19. Huezo-Diaz P, Uher R, Smith R, et al. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry. 2009;195(1):30-38.
20. Ising M, Lucae S, Binder EB, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009;66(9):966-975.
21. D'Empaire I, Guico-Pabia CJ, Preskorn SH. Antidepressant treatment and altered CYP2D6 activity: Are pharmacokinetic variations clinically relevant? J Psychiatr Pract. 2011;17(5):330-339.
22. Konarski JZ, Kennedy SH, Segal ZV, et al. Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. J Psychiatry Neurosci. 2009;34(3):175-180.
23. Kennedy SH, Konarski JZ, Segal ZV, et al. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry. 2007;164(5):778-788. (Pubitemid 46808533)
24. DeBattista C, Kinrys G, Hoffman D, et al. The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. J Psychiatr Res. 2011;45(1):64-75.
25. Leuchter AF, Cook IA, Marangell LB, et al. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: Results of the BRITE-MD study. Psychiatry Res. 2009;169(2): 124-131.
26. Conway CR, Chibnall JT, Gangwani S, et al. Pretreatment cerebral metabolic activity correlates with antidepressant efficacy of vagus nerve stimulation in treatment-resistant major depression: A potential marker for response? J Affect Disord. 2012;139(3):283-290.
27. Siegle GJ, Thompson WK, Collier A, et al. Toward clinically useful neuroimaging in depression treatment: Prognostic utility of subgenual cingulate activity for determining depression outcome in cognitive therapy across studies, scanners, and patient characteristics. Arch Gen Psychiatry. 2012;69(9):913-924.
28. Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in depression: A potential predictor of treatment response. Neuroreport. 1997;8(4):1057-1061. (Pubitemid 27152174)
29. Pizzagalli D, Pascual-Marqui RD, Nitschke JB, et al. Anterior cingulate activity as a predictor of degree of treatment response in major depression: Evidence from brain electrical tomography analysis. Am J Psychiatry. 2001;158(3):405-415. (Pubitemid 32205197)
30. Wu J, Buchsbaum MS, Gillin JC, et al. Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Am J Psychiatry. 1999;156(8):1149-1158. (Pubitemid 29374872)
31. Dougherty DD,Weiss AP, Cosgrove GR, et al. Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for treatment of major depression. J Neurosurg. 2003;99(6):1010-1017. (Pubitemid 44717397)
32. Brody AL, Saxena S, Stoessel P, et al. Regional brainmetabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: Preliminary findings. Arch Gen Psychiatry. 2001;58(7):631-640. (Pubitemid 32640857)
33. Ketter TA, Kimbrell TA, George MS, et al. Baseline cerebral hypermetabolism associated with carbamazepine response, and hypometabolism with nimodipine response in mood disorders. Biol Psychiatry. 1999;46(10):1364-1374.
34. Goldapple K, Segal Z, Garson C, et al. Modulation of cortical-limbic pathways in major depression: Treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry. 2004;61(1): 34-41. (Pubitemid 38044639)
35. Beck A, Rush A, Shaw B, Emery G. Cognitive Therapy of Depression. New York, NY: Guilford; 1979.
36. Beck AT. The current state of cognitive therapy: A 40-year retrospective. Arch Gen Psychiatry. 2005;62(9):953-959. (Pubitemid 41248374)
37. Bartlett EJ, Barouche F, Brodie JD, et al. Stability of resting deoxyglucose metabolic values in PET studies of schizophrenia. Psychiatry Res. 1991;40(1):11-20.
38. Brody AL, Saxena S, Silverman DH, et al. Brain metabolic changes in major depressive disorder from pre-to post-treatment with paroxetine. Psychiatry Res. 1999;91(3):127-139. (Pubitemid 29474048)
39. Kimbrell TA, Ketter TA, George MS, et al. Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biol Psychiatry. 2002;51(3):237-252. (Pubitemid 34142636)
40. DrevetsWC, Price JL, Bardgett ME, Reich T, Todd RD, RaichleME. Glucose metabolism in the amygdala in depression: Relationship to diagnostic subtype and plasma cortisol levels. Pharmacol Biochem Behav. 2002;71(3):431-447. (Pubitemid 34126368)
41. Saxena S, Brody AL, HoML, Zohrabi N, Maidment KM, Baxter LR Jr. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry. 2003;160(3):522-532. (Pubitemid 41094261)
42. Little JT, Ketter TA, Kimbrell TA, et al. Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biol Psychiatry. 2005;57(3): 220-228. (Pubitemid 40187365)
43. MilakMS, Parsey RV, Lee L, et al. Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment. Psychiatry Res. 2009;173(1):63-70.
44. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient EditionWith Psychotic Screen (SCID-I/PW/PSY SCREEN). New York: Biometrics Research, New York State Psychiatric Institute; 2002.
45. Dunlop BW, KelleyME, Mletzko TC, Velasquez CM, Craighead WE,Mayberg HS. Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder. J Psychiatr Res. 2012;46(3):375-381.
46. HamiltonM. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
47. Rush AJ, Trivedi MH, Stewart JW, et al. Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168(7):689-701.
48. Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry. 2000;157(9):1423-1428.
49. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: Validation of method. Ann Neurol. 1979;6(5):371-388. (Pubitemid 10203423)
50. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38(1): 95-113. (Pubitemid 47440133)
51. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associated; 1988.
52. Critchley HD,Wiens S, Rotshtein P, Ohman A, Dolan RJ. Neural systems supporting interoceptive awareness. Nat Neurosci. 2004;7(2):189-195. (Pubitemid 38129796)
53. Farb NA, Segal ZV, Anderson AK. Attentional modulation of primary interoceptive and exteroceptive cortices. Cereb Cortex. 2013;23(1): 114-126.
54. Craig AD. How do you feel-now? The anterior insula and human awareness. Nat Rev Neurosci. 2009;10(1):59-70.
55. Critchley HD. Neural mechanisms of autonomic, affective, and cognitive integration. J Comp Neurol. 2005;493(1):154-166. (Pubitemid 41636198)
56. Augustine Jr. Circuitry and functional aspects of the insular lobe in primates including humans. Brain Res Brain Res Rev. 1996;22(3):229-244. (Pubitemid 26390178)
57. Takahashi T, Yücel M, Lorenzetti V, et al. Volumetric MRI study of the insular cortex in individuals with current and past major depression. J Affect Disord. 2010;121(3):231-238.
58. Kennedy SH, Evans KR, Krüger S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry. 2001;158(6):899-905. (Pubitemid 32547619)
59. Conway CR, Sheline YI, Chibnall JT, George MS, Fletcher JW,MintunMA. Cerebral blood flow changes during vagus nerve stimulation for depression. Psychiatry Res. 2006;146(2):179-184.
60. Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45(5):651-660. (Pubitemid 40320700)
61. Farb NAS, Segal ZV,Mayberg H, et al. Attending to the present:Mindfulness meditation reveals distinct neural modes of self-reference. Soc Cogn Affect Neurosci. 2007;2(4):313-322. (Pubitemid 350186993)
62. Fu CH, Steiner H, Costafreda SG. Predictive neural biomarkers of clinical response in depression: Ameta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiol Dis. 2013;52: 75-83.
63. Pizzagalli DA. Frontocingulate dysfunction in depression: Toward biomarkers of treatment response. Neuropsychopharmacology. 2011;36(1): 183-206.
64. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: An important outcome in depression. Psychol Med. 1995;25(6):1171-1180.
65. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry. 2000;157(9):1501-1504.
66. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12): 836-843. (Pubitemid 30165206)
67. Ridker PM. Cardiology Patient Page. C-reactive protein: A simple test to help predict risk of heart attack and stroke. Circulation. 2003;108(12): E81-e85.
68. Gaynes BN, Dusetzina SB, Ellis AR, et al. Treating depression after initial treatment failure: Directly comparing switch and augmenting strategies in STAR*D. J Clin Psychopharmacol. 2012;32(1):114-119.
69. ThaseME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: A STAR*D report. Am J Psychiatry. 2007;164(5):739-752. (Pubitemid 46808529)
70. Rush AJ,Warden D, Wisniewski SR, et al. STAR?D: Revising conventional wisdom. CNS Drugs. 2009;23(8):627-647.
71. Dunlop BW, Binder EB, Cubells JF, et al. Predictors of remission in depression to individual and combined treatments (PReDICT): Study protocol for a randomized controlled trial. Trials. 2012;13(1):106.
72. Kennedy SH, Downar J, Evans KR, et al. The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in response prediction. Curr Pharm Des. 2012;18(36): 5976-5989.